MA26797A1 - Nouveaux inhibiteurs selectifs de sous-types recepteurs de nmda. - Google Patents

Nouveaux inhibiteurs selectifs de sous-types recepteurs de nmda.

Info

Publication number
MA26797A1
MA26797A1 MA26438A MA26438A MA26797A1 MA 26797 A1 MA26797 A1 MA 26797A1 MA 26438 A MA26438 A MA 26438A MA 26438 A MA26438 A MA 26438A MA 26797 A1 MA26797 A1 MA 26797A1
Authority
MA
Morocco
Prior art keywords
types
nmda receptor
selective inhibitors
novel selective
receptor sub
Prior art date
Application number
MA26438A
Other languages
English (en)
Inventor
Alexander Alanine
Serge Burner
Neidhart Marie-Paule Heitz
Georg Jaeschke
Rene Wyler
Bernd Buettelmann
Emmanuel Pinard
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26797A1 publication Critical patent/MA26797A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA26438A 1999-06-08 2001-12-07 Nouveaux inhibiteurs selectifs de sous-types recepteurs de nmda. MA26797A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99111126 1999-06-08

Publications (1)

Publication Number Publication Date
MA26797A1 true MA26797A1 (fr) 2004-12-20

Family

ID=8238316

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26438A MA26797A1 (fr) 1999-06-08 2001-12-07 Nouveaux inhibiteurs selectifs de sous-types recepteurs de nmda.

Country Status (38)

Country Link
US (1) US6310213B1 (fr)
EP (1) EP1189886B1 (fr)
JP (1) JP3645856B2 (fr)
KR (1) KR100571162B1 (fr)
CN (1) CN1142141C (fr)
AR (1) AR024282A1 (fr)
AT (1) ATE315025T1 (fr)
AU (1) AU770787B2 (fr)
BR (1) BR0011419A (fr)
CA (1) CA2376091C (fr)
CO (1) CO5160328A1 (fr)
CZ (1) CZ299483B6 (fr)
DE (1) DE60025348T2 (fr)
DK (1) DK1189886T3 (fr)
EG (1) EG26101A (fr)
ES (1) ES2254183T3 (fr)
GC (1) GC0000256A (fr)
GT (1) GT200000089A (fr)
HK (1) HK1046412B (fr)
HR (1) HRP20010885B1 (fr)
HU (1) HU228591B1 (fr)
IL (2) IL146750A0 (fr)
JO (1) JO2260B1 (fr)
MA (1) MA26797A1 (fr)
MX (1) MXPA01012585A (fr)
MY (1) MY128818A (fr)
NO (1) NO320613B1 (fr)
PA (1) PA8496601A1 (fr)
PE (1) PE20010218A1 (fr)
PL (1) PL196053B1 (fr)
RS (1) RS50033B (fr)
RU (1) RU2242464C2 (fr)
SI (1) SI1189886T1 (fr)
TN (1) TNSN00125A1 (fr)
TR (1) TR200103532T2 (fr)
TW (1) TWI254043B (fr)
WO (1) WO2000075109A1 (fr)
ZA (1) ZA200109706B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2225330T3 (es) * 2000-03-22 2005-03-16 Hoffmann La Roche Compuesto de piperidina y piperacina para empleo en el tratamiento de alzheimer.
ATE274494T1 (de) * 2000-04-20 2004-09-15 Hoffmann La Roche Pyrrolidin und piperidin derivate für die behandlung von neurodegenerativen erkrankungen
PE20020291A1 (es) * 2000-08-21 2002-04-17 Hoffmann La Roche Profarmacos para ligandos del receptor nmda
JP4228048B2 (ja) * 2000-10-09 2009-02-25 ピーオーダブリューエムアールアイ リミテッド 神経変性障害の検出方法
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
RU2268715C1 (ru) * 2004-06-22 2006-01-27 ГУ "Научно-исследовательский институт экспериментальной медицины" РАМН (ГУ НИИЭМ РАМН) Нейропротекторное средство
MX2010009649A (es) * 2008-03-27 2010-12-17 Evotecv Neurosciences Gmbh Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda.
EP2734041A4 (fr) * 2011-07-18 2015-03-25 Adolor Corp Procédés de préparation de composés antagonistes des opioïdes périphériques et des intermédiaires de ceux-ci
WO2024217539A1 (fr) * 2023-04-20 2024-10-24 纽欧申医药(上海)有限公司 Composé hétérocyclique contenant de l'azote, son procédé de préparation et son utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0594729A1 (fr) * 1991-07-17 1994-05-04 Pfizer Inc. Derives 2-(4-hydroxypiperidino)-1-alcanol utilises comme agents anti-ischemiques
DE4410822A1 (de) * 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives

Also Published As

Publication number Publication date
CZ20014349A3 (cs) 2002-05-15
WO2000075109A1 (fr) 2000-12-14
JO2260B1 (en) 2004-10-07
GC0000256A (en) 2006-11-01
CN1354745A (zh) 2002-06-19
IL146750A0 (en) 2002-07-25
AR024282A1 (es) 2002-09-25
US6310213B1 (en) 2001-10-30
GT200000089A (es) 2001-11-29
HRP20010885B1 (en) 2010-07-31
TR200103532T2 (tr) 2002-05-21
PL352723A1 (en) 2003-09-08
EP1189886B1 (fr) 2006-01-04
DE60025348D1 (de) 2006-03-30
ATE315025T1 (de) 2006-02-15
CZ299483B6 (cs) 2008-08-13
EP1189886A1 (fr) 2002-03-27
NO320613B1 (no) 2005-12-27
KR20020008850A (ko) 2002-01-31
HRP20010885A2 (en) 2004-02-29
DE60025348T2 (de) 2006-08-24
RS50033B (sr) 2008-11-28
TNSN00125A1 (fr) 2005-11-10
HUP0201916A3 (en) 2003-05-28
AU770787B2 (en) 2004-03-04
IL146750A (en) 2006-12-10
HU228591B1 (hu) 2013-04-29
CA2376091A1 (fr) 2000-12-14
KR100571162B1 (ko) 2006-04-17
CN1142141C (zh) 2004-03-17
EG26101A (en) 2013-02-17
RU2242464C2 (ru) 2004-12-20
ES2254183T3 (es) 2006-06-16
MY128818A (en) 2007-02-28
PE20010218A1 (es) 2001-02-28
SI1189886T1 (sl) 2006-04-30
ZA200109706B (en) 2003-02-26
JP2003501415A (ja) 2003-01-14
PL196053B1 (pl) 2007-11-30
HUP0201916A2 (en) 2002-10-28
HK1046412B (zh) 2004-07-09
PA8496601A1 (es) 2001-12-14
AU5218100A (en) 2000-12-28
CO5160328A1 (es) 2002-05-30
CA2376091C (fr) 2006-03-14
DK1189886T3 (da) 2006-05-15
NO20015920D0 (no) 2001-12-04
HK1046412A1 (en) 2003-01-10
BR0011419A (pt) 2002-02-26
MXPA01012585A (es) 2002-04-10
NO20015920L (no) 2001-12-04
JP3645856B2 (ja) 2005-05-11
YU86501A (sh) 2004-09-03
TWI254043B (en) 2006-05-01

Similar Documents

Publication Publication Date Title
MXPA03000059A (es) Derivados de pirazol.
FR12C0007I2 (fr) Nouveaux derives de phenyle-propargylether
DK1202638T4 (da) Fremgangsmåde til fremstilling af beluftede, frosne produkter
BR0113449B1 (pt) aparelho peneirador.
MA26060A1 (fr) Nouveaux derives de pyrazolopyridine
EE200300246A (et) EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks
DE60025241D1 (de) HäMOPOIETINREZEPTOR-PROTEIN, NR12
DE60041964D1 (de) Empfänger
DE60142269D1 (de) Lautsprechersystem
MA26895A1 (fr) Derives de cyclohexylamine antagonistes des recepteurs de nmda, selectifs vis-a-vis de sous-types
DE60127963D1 (de) Signalübertragungssystem
EP1339208A4 (fr) Systeme de teleconference
IT1319240B1 (it) Procedimento per la oligomerizzazione selettiva dell'etilene.
DE60128587D1 (de) Lactamverbindungen
MA26797A1 (fr) Nouveaux inhibiteurs selectifs de sous-types recepteurs de nmda.
DE60132196D1 (de) Testsignalisierung
DE60132068D1 (de) Empfangsgerät
DK1178990T3 (da) Imidazodiazepinderivat.
AR028607A1 (es) Derivados de 1,4-diazepan-2,5-diona
DE60103664D1 (de) Schwarzschulterklemmung
DE60028867D1 (de) Verzögerungsleitung
EP1405905A4 (fr) Dispositif de synthese de chaines glucidiques
DE60136218D1 (de) Stentablegesystem
FR2818339B1 (fr) Dispositif de synchronisation compact
FR2818576B1 (fr) Fendeur de buche